In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

The stock's fall snapped a seven-day winning streak.

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Read Our Latest Analysis on Biogen Biogen Trading Up 0.4 % Shares of NASDAQ:BIIB opened at $140.50 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

As of 24 February at 15:46:45 GMT-5. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as ...